Haemonetics Co. (NYSE:HAE) Given Average Recommendation of “Moderate Buy” by Analysts

Haemonetics Co. (NYSE:HAE) has received an average rating of “Moderate Buy” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $106.14.

HAE has been the topic of a number of analyst reports. CL King initiated coverage on Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and issued a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 13th. Barrington Research reiterated an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a research note on Monday, September 23rd. Bank of America began coverage on Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price target for the company. Finally, BTIG Research began coverage on Haemonetics in a research note on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price target for the company.

Haemonetics Stock Up 1.9 %

Shares of NYSE HAE opened at $74.93 on Friday. Haemonetics has a 1 year low of $70.25 and a 1 year high of $97.97. The firm has a market cap of $3.83 billion, a price-to-earnings ratio of 33.60, a PEG ratio of 1.12 and a beta of 0.32. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76. The stock’s 50-day simple moving average is $75.36 and its 200-day simple moving average is $82.63.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The business had revenue of $336.17 million for the quarter, compared to analysts’ expectations of $335.08 million. During the same period in the previous year, the firm posted $1.05 earnings per share. The firm’s revenue was up 8.0% compared to the same quarter last year. As a group, equities analysts anticipate that Haemonetics will post 4.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. boosted its stake in Haemonetics by 0.6% in the third quarter. Victory Capital Management Inc. now owns 278,886 shares of the medical instruments supplier’s stock valued at $22,417,000 after acquiring an additional 1,717 shares during the period. Aigen Investment Management LP acquired a new position in Haemonetics in the third quarter valued at approximately $479,000. Versor Investments LP raised its holdings in shares of Haemonetics by 9.1% during the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 300 shares during the last quarter. State of New Jersey Common Pension Fund D raised its holdings in shares of Haemonetics by 22.0% during the third quarter. State of New Jersey Common Pension Fund D now owns 25,932 shares of the medical instruments supplier’s stock valued at $2,084,000 after buying an additional 4,672 shares during the last quarter. Finally, First Personal Financial Services raised its holdings in shares of Haemonetics by 2.9% during the third quarter. First Personal Financial Services now owns 11,110 shares of the medical instruments supplier’s stock valued at $893,000 after buying an additional 312 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.